NCI Cancer Moonshot Funding Opportunities Align With ASH's Research Priorities
ASH is pleased to see the National Cancer Institute’s (NCI) continuous support for research aimed at accelerating the prevention and treatment of cancers. ASH submitted recommendations in 2016 to the Cancer Moonshot Blue Ribbon Panel in response to the NCI’s request for information on high priority areas that should be supported by the Cancer Moonshot Initiative. Based on ASH’s research priorities, the Society called for research support in the following areas:
- Improved early cancer detection and prevention
- Understanding tumor development and progression
- Pediatric cancers
- Improved access to clinical trials of novel targeted therapies for hematologic cancers
- Development of immune-based therapies for hematologic cancers
- Enhanced data sharing
Several of the NCI Cancer Moonshot funding opportunities, including those listed below, are in alignment with ASH’s recommendations for research support that were shared with the Cancer Moonshot Blue Ribbon Panel.
- Pre-Cancer Atlas (PCA) Research Centers (U2C) -
- Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) -
- Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24) -
- Metabolic Reprogramming to Improve Immunotherapy (R01) -
- Metabolic Reprogramming to Improve Immunotherapy (R21) -
- Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01) -
These funding opportunities will help foster hematology research and will have a great impact on the development of potentially life-saving treatments for patients with hematologic cancers. For a comprehensive list of all Cancer Moonshot funding opportunities, please visit the .
